New HIV Drug Reaches 9 African Nations in Record Time

A medicine that prevents nearly 100% of HIV infections with just two injections per year is now reaching people across nine African countries, marking the most significant breakthrough in HIV prevention in nearly 40 years.

The World Health Organization announced it has supported the rollout of lenacapavir in Eswatini, Kenya, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe. WHO Director-General Tedros Ghebreyesus called it a historic milestone in the global fight to end the HIV epidemic.

Lenacapavir isn't a vaccine. It's a long-acting drug given twice yearly to HIV-negative people who face substantial risk of infection. Clinical trials show it can prevent almost all new infections in high-risk individuals, making it one of the most powerful prevention tools ever developed.

The speed of this rollout breaks all precedents. WHO issued treatment guidelines in July 2024 and granted product prequalification by October, the first time these steps happened simultaneously rather than years apart. That fast-tracking means life-saving medication reached vulnerable populations in just eight months instead of the usual multi-year wait.

South Africa became the first African nation to approve lenacapavir last October, only the third country worldwide to authorize it. President Cyril Ramaphosa announced plans for a large-scale national rollout, and this week South Africa revealed it will manufacture the drug locally, a game-changer for regional access and supply.

The impact potential is enormous. AIDS-related deaths have already dropped 70% globally over the past two decades as treatment improved. Now this prevention drug could protect millions more people before they're ever exposed to HIV, particularly in regions where the virus remains a major health threat.

The Ripple Effect

Demand is already outpacing supply, with country orders through international donors falling short of need. WHO is working urgently with governments, donors, and pharmaceutical manufacturers to scale up production and ensure supplies reach the countries introducing the medicine.

South Africa's decision to manufacture lenacapavir locally could transform access across the entire African continent. Local production means faster distribution, lower costs, and greater control over supply chains for neighboring nations.

The broader public health momentum extends beyond HIV. Nearly 60 countries have launched HPV vaccination programs since WHO's 2018 cervical cancer elimination initiative, with 162 countries now including the vaccine in national schedules. India launched the world's largest free HPV vaccination campaign in February, targeting 12 million girls annually.

These parallel advances in HIV prevention and cancer elimination show what's possible when global health organizations, governments, and manufacturers collaborate at unprecedented speed. What once took decades now happens in months.

Millions of people who might have faced HIV infection now have access to protection that requires just two doctor visits per year.